These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 16200937

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP, McMahon GT.
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association, American Diabetes Association.
    Circulation; 2003 Dec 09; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract] [Full Text] [Related]

  • 26. Rational choice of oral antihyperglycaemic agents.
    Chowdhury S, Sengupta N.
    J Indian Med Assoc; 2002 Mar 09; 100(3):174-5, 177. PubMed ID: 12408278
    [Abstract] [Full Text] [Related]

  • 27. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug 09; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 09; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.
    Pharmacoepidemiol Drug Saf; 2007 May 09; 16(5):504-12. PubMed ID: 17245800
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.
    Roselli A, Hayes JD, Seidner R, Marchione V, Snyder CM, Mayes K, Stiernberg CM, Milgram L.
    Manag Care; 2001 Feb 09; 10(2 Suppl):17-21. PubMed ID: 11729404
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach.
    Elasy TA, Levy P, Davis SN.
    J Fam Pract; 2004 Oct 09; 53(10):815-22. PubMed ID: 15469778
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.